Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.55 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.48 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3996666 | 0.81 | ALDH1A1 (0.53) | ALDH1A1TRIM24TRIM33GAANPC1 | |
| SCHEMBL6366118 | 0.79 | ALDH1A1 (0.50) | ALDH1A1TRIM24TRIM33GAANPC1 | |
| SCHEMBL5403668 | 0.78 | — | — | |
| SCHEMBL28625554 | 0.75 | ALDH1A1 (0.50) | ALDH1A1TRIM24TRIM33GAANPC1 | |
| SCHEMBL5246675 | 0.75 | ALDH1A1 (0.43) | ALDH1A1TRIM24TRIM33GAANPC1 | |
| SCHEMBL6366217 | 0.74 | ALDH1A1 (0.46) | ALDH1A1TRIM24TRIM33GAANPC1 | |
| SCHEMBL1609235 | 0.74 | ALDH1A1 (0.60) | ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL27618964 | 0.74 | — | — | |
| SCHEMBL6127705 | 0.74 | — | — | |
| SCHEMBL28331384 | 0.73 | TRIM24 (0.48) | ALDH1A1TRIM24TRIM33GAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124625-B2 | enhancing the expression of apoAI; prevention or therapy of dislipidemia | SHIONOGI & CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8053445-B2 | Utilities of olefin derivatives | SHIONOGI & CO., LTD. (JP) | 2011-11-08 | — | — | US | disclosed |
| US-20090036457-A1 | Utilities of olefin derivatives | YAMAMORI TERUO | 2009-02-05 | — | — | US | disclosed |
| US-20040242615-A1 | Utilities of olefin derivatives | SHIONOGI & CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242615-A1 | Utilities of olefin derivatives | APOL1, NR1H2, APOB | ALDH1A1 1967/4885TRIM24 2097/4885TRIM33 4702/4885 |
| US-20090036457-A1 | Utilities of olefin derivatives | APOL1, APOB, NR1H2 | ALDH1A1 1938/4885TRIM24 2152/4885TRIM33 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.